Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study. (4th March 2021)

• Record Type: Journal Article
• Authors: Foster, Shonda A.; Balkaran, Bridget L.; Cambron-Mellott, M. Janelle; Samaan, Karen; Mason, Oksana; Ye, Wenyu; Rowland, John C.; Jaffe, Dena H.
• Is Part Of: Current medical research and opinion. Volume 37:Number 3(2021)
• Page Start: 443
• Page End: 457
• Publication Date: 2021-03-04
• Subjects: Claims -- monthly headache days -- migraine -- National Health and Wellness Survey -- prevention-eligible -- preventive therapy; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2020.1865749
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: To characterize burden of migraine in prevention-eligible patients compared with prevention non-eligible patients in the United States (US). Receipt of preventive therapy was also examined among prevention-eligible patients. Methods: This retrospective study utilized data from the 2017 US National Health and Wellness Survey linked with medical and pharmacy claims. Patients aged ≥18 years who self-reported experiencing migraine and had confirmed evidence of migraine (≥1 medical or pharmacy claim) were included. Prevention eligibility was based on number of headache days in the past 30 days (prevention-eligible: ≥4 and prevention non-eligible: <4). Descriptive statistics summarized study variables; bivariate and multivariable analyses were conducted to examine the association of prevention-eligibility status with outcomes. Results: Analyses included 450 patients, 291 (65%) prevention-eligible, and of these 56 (19%) received preventive therapy. Overall, patients were 42.98 ± 14.51 years old; 84% were female. Prevention-eligible patients reported significantly more migraine headache days in the past 6 months (29.27 ± 37.96 vs. 8.61 ± 7.88), had lower mental component summary scores (35.80 ± 2.73 vs. 37.90 ± 2.96), and more presenteeism (47.30 ± 2.98% vs. 37.90 ± 2.60%), overall work impairment (46.30 ± 2.87% vs. 37.90 ± 2.55%) and activity days missed due to migraine (8.16 ± 3.05 vs. 3.82 ± 1.58) than prevention non-eligible patients (all p <.001). Prevention-eligible patients receiving preventive therapy reported more migraine headache days during the past month (9.21 ± 7.99 vs. 6.06 ± 7.10; p =.002) and activity days lost due to migraine (18.39 ± 28.08 vs. 10.69 ± 21.43, p =.015) than those not receiving preventive therapy. Conclusions: Prevention-eligible patients experience greater burden due to migraine, including more headache days, worse health-related quality-of-life, and greater work and activity impairment than prevention non-eligible patients.